{
    "clinical_study": {
        "@rank": "73910", 
        "arm_group": [
            {
                "arm_group_label": "Brimonidine Tartrate", 
                "arm_group_type": "Experimental", 
                "description": "Brimonidine tartrate ophthalmic solution 0.025%, one drop of drug into each eye, four times daily for up to four weeks."
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle of brimonidine tartrate ophthalmic solution, one drop of vehicle into each eye, four times daily, for up to four weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025%\n      versus its vehicle in a population of pediatric, adult, and geriatric subjects. At least 51%\n      of subjects will be 40 years of age or older."
        }, 
        "brief_title": "Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperemia", 
        "condition_browse": {
            "mesh_term": "Hyperemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must be at least 5 years of age at Visit 1 of either sex gender and any\n             race or ethnicity;\n\n          -  Have ocular health within normal limits, including a calculated best- corrected (if\n             necessary) visual acuity of 0.3 logMAR or better in each eye, as measured using an\n             Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.\n\n        Exclusion Criteria:\n\n          -  Have any ocular/systemic health problems\n\n          -  Use of any disallowed medications during the period indicated prior to Visit 1 and\n             for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959243", 
            "org_study_id": "862"
        }, 
        "intervention": [
            {
                "arm_group_label": "Brimonidine Tartrate", 
                "intervention_name": "Brimonidine Tartrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Ocular redness", 
        "lastchanged_date": "January 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07940"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.", 
        "overall_contact": {
            "email": "kris.hartman@bausch.com", 
            "last_name": "Kris Hartman", 
            "phone": "585-338-5165"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Quintus Ngumah, OD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of adverse events in the treated group vs vehicle group", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Overall visits to Visit 4 (Day 36)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959243"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured on a scale of 0-10.", 
                "measure": "Drop Comfort", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (Day 1)"
            }, 
            {
                "description": "Alertness measured at 90-180 minutes after administration of the test product using a 6 point alertness scale.", 
                "measure": "Alertness", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (Day 15), Visit 3 (Day 29), and Visit 4 (Day 36)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}